130 related articles for article (PubMed ID: 17396539)
1. Pharmacological management of secreting pituitary tumors.
Gordon BM
J Neurosci Nurs; 2007 Feb; 39(1):52-7. PubMed ID: 17396539
[TBL] [Abstract][Full Text] [Related]
2. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
Cuny T; Barlier A; Feelders R; Weryha G; Hofland LJ; Ferone D; Gatto F
Ann Endocrinol (Paris); 2015 Feb; 76(1):43-58. PubMed ID: 25556152
[TBL] [Abstract][Full Text] [Related]
3. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
4. Ectopic growth hormone-secreting pituitary adenoma involving the clivus treated with octreotide: role of magnetic resonance imaging in the diagnosis and clinical follow-up.
Ferraz-Filho JR; Torres US; Teixeira AC; Castro ML; Dias MA
Arq Neuropsiquiatr; 2012 Sep; 70(9):744-5. PubMed ID: 22990736
[No Abstract] [Full Text] [Related]
5. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
6. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
Raverot G; Jouanneau E; Trouillas J
Eur J Endocrinol; 2014 Apr; 170(4):R121-32. PubMed ID: 24431196
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
8. Response of ACTH to octreotide in a probable corticotropic adenoma associated with Addison's disease.
Suárez-Llanos JP; Fernández-Fernández E; Checa MR; Jara-Albarrán A
Neuro Endocrinol Lett; 2007 Oct; 28(5):549-53. PubMed ID: 17984930
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic difficulties in an aggressive ACTH-secreting pituitary adenoma.
Foltyn W
Endokrynol Pol; 2022; 73(2):375-376. PubMed ID: 35381097
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) and guanylate kinase 1 (GUK1) are differentially expressed in GH-secreting adenomas.
da Rocha AA; Giorgi RR; de Sa SV; Correa-Giannella ML; Fortes MA; Cavaleiro AM; Machado MC; Cescato VA; Bronstein MD; Giannella-Neto D
Pituitary; 2006; 9(2):83-92. PubMed ID: 16832584
[TBL] [Abstract][Full Text] [Related]
11. Clinical and epidemiological characteristics of pituitary tumours in a single centre in Saudi Arabia.
Hussein SH; Wahedi TS; Johani NA; Hakami YA; Alzahrani K; AlMalki MH
Hormones (Athens); 2018 Jun; 17(2):261-267. PubMed ID: 29858852
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF therapy in pituitary carcinoma.
Ortiz LD; Syro LV; Scheithauer BW; Ersen A; Uribe H; Fadul CE; Rotondo F; Horvath E; Kovacs K
Pituitary; 2012 Sep; 15(3):445-9. PubMed ID: 21918831
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
14. Management of aggressive growth hormone secreting pituitary adenomas.
Donoho DA; Bose N; Zada G; Carmichael JD
Pituitary; 2017 Feb; 20(1):169-178. PubMed ID: 27987061
[TBL] [Abstract][Full Text] [Related]
15. Inoperable Giant Growth Hormone-secreting Pituitary Adenoma: Radiological Aspects, Clinical Management and Pregnancy Outcome.
Dicuonzo F; Purciariello S; De Marco A; Guastamacchia E; Triggiani V
Endocr Metab Immune Disord Drug Targets; 2019; 19(2):214-220. PubMed ID: 30088454
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
17. Ectopic Adrenocorticotropic Hormone-Secreting Pituitary Adenomas: An Underestimated Entity.
Knappe UJ; Jaspers C; Buschsieweke D; Reinbold WD; Alomari A; Saeger W; Ehlenz K; Mann WA; Kann PH; Feldkamp J
Neurosurgery; 2017 Apr; 80(4):525-533. PubMed ID: 27352274
[TBL] [Abstract][Full Text] [Related]
18. AT-101 acts as anti-proliferative and hormone suppressive agent in mouse pituitary corticotroph tumor cells.
Yurekli BS; Karaca B; Kisim A; Bozkurt E; Atmaca H; Cetinkalp S; Ozgen G; Yilmaz C; Uzunoglu S; Uslu R; Saygili F
J Endocrinol Invest; 2018 Feb; 41(2):233-240. PubMed ID: 28730425
[TBL] [Abstract][Full Text] [Related]
19. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.
Bergamaschi S; Ronchi CL; Giavoli C; Ferrante E; Verrua E; Ferrari DI; Lania A; Rusconi R; Spada A; Beck-Peccoz P
Horm Res Paediatr; 2010; 73(1):74-9. PubMed ID: 20190543
[TBL] [Abstract][Full Text] [Related]
20. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
